The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

CDC vaccine advisors are set to discuss recommendations for the vaccine on Feb. 26. The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best vaccine stocks to buy now. On February 24, CNBC reported that President Trump declared that ...

Feb 15 (Reuters) - The U.S. Food and Drug Administration approved British drugmaker GSK's (GSK.L), opens new tab combination vaccine to protect against meningococcal infection for use in people ...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that GSK plc (LON:GSK) is about to go ex-dividend in just ...

The shares of GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) jumped over 15 percent to trade at Rs 2,684 apiece on February 18, extending gains for the second straight session after releasing ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the ...